PeptiDream Announces Achievement of Development Milestone in Collaboration with MSD
Filed with TSE · · 2 pages · English
Summary by 6ix AI
PeptiDream Inc. announced the achievement of a development milestone in its collaboration with MSD, which has triggered a milestone payment to PeptiDream. This milestone reflects the ongoing progress of their peptide cytotoxic conjugate program under the collaboration agreement. The company emphasized the versatility of its Peptide Discovery Platform System in this emerging therapeutic area. PeptiDream confirmed that this achievement has been included in their financial forecasts for the fiscal year ending in the future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/peptidream-announces-achievement-of-development-milestone-in-collaboration-with-msd
Story so far
Earlier from PeptiDream
- Consolidated Financial Results for the Six Months Ended June 30, 2026 [IFRS]
- Initiation of Phase 1 Clinical Trial by Novartis Marks Milestone for PeptiDream
- PeptiDream Strengthens Leadership Team with Multiple Key Executive Appointments
- PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
- PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Later from PeptiDream
All PeptiDream news releasesFollow PeptiDream into a list and get an email when it puts out news.
Follow PeptiDream